​

Marker Therapeutics (MRKR) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

MRKR Stock Rating

Marker Therapeutics stock's rating consensus is Buy, based on 5 Wall Street analysts. The breakdown includes 1 Strong Buy (20.00%), 2 Buy (40.00%), 2 Hold (40.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 5 0 2 2 1 Strong Sell Sell Hold Buy Strong Buy

MRKR Price Target Upside V Benchmarks

TypeNameUpside
StockMarker Therapeutics-
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$1.40$1.40$1.40
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 26-3---3
Mar, 26-3---3
Feb, 26-3---3
Jan, 26-3---3
Dec, 25-2---2
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Dec 08, 2025H.C. WainwrightBuyinitialise
Dec 08, 2025H.C. WainwrightBuyBuyhold
Mar 05, 2025Canaccord GenuityBuyinitialise
Mar 21, 2021Cantor FitzgeraldOverweightinitialise

Financial Forecast

EPS Forecast

Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$-3.58$-1.93$-1.19$-0.79--
Avg Forecast$-3.60$-3.40$-1.05$-2.19$-2.59$-1.13
High Forecast$-3.60$-3.40$-1.05$-2.19$-2.59$-1.13
Low Forecast$-3.60$-3.40$-1.05$-2.19$-2.59$-1.13
Surprise %-0.56%-43.24%13.33%-63.93%--

Revenue Forecast

$0 $800B $2T $2T $3T $4T Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$3.51M$3.31M$6.59M$3.55T--
Avg Forecast$9.00M$3.31M$5.34M$4.00M$2.00M$37.97M
High Forecast$9.00M$3.31M$5.34M$4.00M$2.00M$37.97M
Low Forecast$9.00M$3.31M$5.34M$4.00M$2.00M$37.97M
Surprise %-60.96%-23.45%88666625.00%--

Net Income Forecast

$-15T $-12T $-9T $-6T $-3T $0 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$-29.93M$-8.24M$-10.73M$-12.16T--
Avg Forecast$-31.71M$-29.95M$-9.25M$-19.29M$-22.82M$-9.95M
High Forecast$-31.71M$-29.95M$-9.25M$-19.29M$-22.82M$-9.95M
Low Forecast$-31.71M$-29.95M$-9.25M$-19.29M$-22.82M$-9.95M
Surprise %-5.62%-72.50%16.02%63048181.65%--

MRKR Forecast FAQ

Is Marker Therapeutics stock a buy?

Marker Therapeutics stock has a consensus rating of Buy, based on 5 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 2 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Marker Therapeutics is a favorable investment for most analysts.

What is Marker Therapeutics's price target?

Marker Therapeutics's price target, set by 5 Wall Street analysts, averages - over the next 12 months. The price target range spans from - at the low end to - at the high end, suggesting a potential 0% change from the previous closing price of $1.4.

How does Marker Therapeutics stock forecast compare to its benchmarks?

Marker Therapeutics's stock forecast shows a 0% downside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Marker Therapeutics over the past three months?

  • April 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • March 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Marker Therapeutics’s EPS forecast?

Marker Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-2.59, marking a 227.85% increase from the reported $-0.79 in 2025. Estimates for the following years are.

What is Marker Therapeutics’s revenue forecast?

Marker Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $2M, reflecting a -100.00% decrease from the reported $3.55T in 2025. The forecast for.

What is Marker Therapeutics’s net income forecast?

Marker Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-22.816M, representing a -100.00% decrease from the reported $-12.164T in 2025. Projections indicate .